TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06025929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maitland's mobilization technique
Description: Maitland's mobilization technique was performed on the patients with its all components, such as 1. Distraction 2. Anteroposterior glides 3. Posteroanterior glides 4. Medial glides and 5. Lateral glides.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mulligan's mobilization techniques
Description: Mulligan's mobilization technique was performed on the patients with its all components using a therapeutic belt, such as 1. Medial mobilization with movement (MWM) for Knee flexion 2. Medial mobilization with movement (MWM) for Knee extension 3. Lateral mobilization with movement (MWM) for Knee flexion 4. Lateral mobilization with movement (MWM) for Knee extension.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interferential Therapy (IFT)
Description: Interferential Therapy was performed on the patients with the following parameters: career frequency 4000Hz; waveform: rectangular; sweep time: 1 second rise and fall and 5 second stay; Treatment duration: 10 minutes; sweep frequency: 10 to 130 Hz. The current intensity was adjusted until the subject reported feeling a strong tingling sensation without causing muscle contraction. A aquatic gel was applied before straping the electopads over treatment area for smooth electrical conduction.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Therapy (IFT)
Description: Interferential Therapy was performed on the patients with the following parameters: career frequency 4000Hz; waveform: rectangular; sweep time: 1 second rise and fall and 5 second stay; Treatment duration: 10 minutes; sweep frequency: 10 to 130 Hz. The current intensity was adjusted until the subject reported feeling a strong tingling sensation without causing muscle contraction. A aquatic gel was applied before straping the electopads over treatment area for smooth electrical conduction.
Study: NCT02818491

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline 0.9% in 2 mls

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 1 mg
Description: Dexamethasone 1 mg in 2 mls

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 2 mg
Description: Dexamethasone 2 mg in 2 mls

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 3 mg
Description: Dexamethasone 3 mg in 2 mls

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: Dexamethasone 4 mg in 2 mls

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% 20 mls

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% 20 mls

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% 20 mls

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% 20 mls

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5%
Description: Ropivacaine 0.5% 20 mls
Study: NCT01604759

Intervention type: DEVICE
Group type: OTHER
Intervention: Polarized Reflectance Spectroscopy System
Description: Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
Study: NCT02732080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: deferred coronary stenting
Description: Final coronary stenting will be performed when coronary auto regulation was recovered (approximately 30 minutes after establishment of TIMI III flow şn the infarct related artery)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: immediate stenting
Description: Stent implantation will be performed immediately after balloon angioplasty (or thrombectomy or wire crossing) as it is performed in daily routine.
Study: NCT02942589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal portion size

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal portion size
Study: NCT02057380

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subcutaneous or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subcutaneous or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subcutaneous or IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV, Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV, Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV, Oral
Study: NCT04159896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pan-VEGFR/TIE2 Tyrosine Kinase Inhibitor CEP-11981
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT02096939

Intervention type: DRUG
Intervention: Antihypertensive medication
Study: NCT02543593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS or Sham tDCS
Description: tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex. In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Active tDCS or Sham tDCS
Description: tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex. In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).
Study: NCT03795779

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLL1-CD33 cCAR T cells
Description: CLL1-CD33 cCAR T cells transduced with a lentiviral vector to express two distinct units of anti-CLL1 and CD33 CARs.
Study: NCT04349579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycine
Description: Local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and bleeding was controlled. Finally, extraction socket was irrigated with the solution which contains 250 mg rifamycine and the mucoperiosteal flap was repositioned by 3.0 silk sutures.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline Solution
Description: Local anesthesia was obtained using 2 ml articaine hydrochloride 40 mg/ml with epinephrine 0.01 mg/ml . The horizontal incision was made with no. 15 scalpel blade and a full thickness mucoperiosteal flap was raised. In all surgical procedures, bone removal and/or tooth sectioning were performed under sterile saline irrigation. Following the extraction, granulation tissues were removed, and post extraction cavity was irrigated with saline solution. After the bleeding was controlled, the mucoperiosteal flap was repositioned by 3.0 silk sutures.
Study: NCT02890056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: H2GO!
Study: NCT04119245

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: I-gel supraglottic airway device
Description: After induction of general anesthesia, we will measure the Oropharyngeal leak airway pressure during controlled ventilation in supine and in positions after insertion of I-gel.
Study: NCT04081545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Anesthetics
Description: see arm/group description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non Opioid Analgesics
Description: see arm/group description
Study: NCT00654238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400mg PO BID daily
Study: NCT00859417

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional surgery
Description: Traditional surgical method without prosthesis (correction of the anterior prolapse through vaginal tract with the use of autologous tissue).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perigee® prosthesis
Description: Surgical method with Perigee® prosthesis
Study: NCT03752736

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: I wear sunscreen everyday song-based video
Description: All four classes (arms) will be shown (sitting on carpet, not participating) a 2-3 minute song-based video titled I wear sunscreen everyday in which they observe elementary age children applying sunscreen in a systematic fashion. Following the viewing, classes will be administered this video guided, song- based intervention while their teacher documents their independent participation using our classroom map data collection sheet.
Study: NCT01340534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen 80% FIO2
Description: Use of oxygen 80% FIO2 during surgery and 2 hours after the procedure. For this purpose an oxygen mask with reservoir will be used (to guarantee the supply of 80% oxygen during and after surgery)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Use of air (no oxygen during surgery)
Description: No use of oxygen during surgery or in the 2 hours after the procedure.
Study: NCT04850742

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryopreserved aorta
Description: After resection of the tracheal or bronchial lesion with standard surgical techniques, the airway gap is reconstructed with a segment of human cryopreserved (-80 celsius degree) aortic allograft, which was not matched by the ABO and leukocyte antigen systems. The anastomosis is performed with standard technique for airway anastomosis. An Ultraflex covered tracheobronchial stent is inserted to prevent collapse for the aortic graft.
Study: NCT02480075

Intervention type: OTHER
Intervention: Observational
Description: Observational Study only
Study: NCT02496988

Intervention type: DRUG
Group type: OTHER
Intervention: Temozolomide
Description: Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: CIK
Description: The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
Study: NCT01164787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trandolapril
Description: Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mavik
Description: Mavik® 4 mg Tablets of Abbott Laboratories, USA.
Study: NCT01305824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRT-201
Description: PRT-201 10 micrograms administered at the time of AVF creation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered at the time of AVF creation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRT-201
Description: PRT-201 30 micrograms administered at the time of AVF creation.
Study: NCT02686567

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: without TDT
Description: After laparoscopic anterior resection and double-stapling technique anastomosis were finished, none additional proceduce was done.
Study: NCT01307358

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sonicare Interproximal (IP) Cleaning Prototype
Description: Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sonicare Interproximal (IP) Cleaning Prototype
Description: Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.
Study: NCT00057811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV, IT, or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV, IT, or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study: NCT03715569

Intervention type: DIAGNOSTIC_TEST
Intervention: Vestibular function
Description: Vhit, Caloric test

Intervention type: DIAGNOSTIC_TEST
Intervention: OAE/WBT
Description: Oto acoustic emissions Wide Band Tympanometry

Intervention type: DIAGNOSTIC_TEST
Intervention: OAE/WBT
Description: Oto acoustic emissions Wide Band Tympanometry

Intervention type: DIAGNOSTIC_TEST
Intervention: OAE/WBT
Description: Oto acoustic emissions Wide Band Tympanometry
Study: NCT00057811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV or IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV or IT
Study: NCT03715569

Intervention type: DIAGNOSTIC_TEST
Intervention: OAE/WBT
Description: Oto acoustic emissions Wide Band Tympanometry

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker
Description: Biomarker examination

Intervention type: DIAGNOSTIC_TEST
Intervention: Biomarker
Description: Biomarker examination

Intervention type: DIAGNOSTIC_TEST
Intervention: MOCA, eGOS
Description: Cognitive tests

Intervention type: DIAGNOSTIC_TEST
Intervention: Audiometry
Description: Hearing test
Study: NCT02508727

Intervention type: OTHER
Group type: OTHER
Intervention: MRI

Intervention type: OTHER
Group type: OTHER
Intervention: MRI

Intervention type: OTHER
Group type: OTHER
Intervention: MRI

Intervention type: OTHER
Group type: OTHER
Intervention: 3D cardiac ultrasound

Intervention type: OTHER
Group type: OTHER
Intervention: 3D cardiac ultrasound

Intervention type: OTHER
Group type: OTHER
Intervention: 3D cardiac ultrasound
Study: NCT02136823

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isradipine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Study: NCT01307358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sonicare Interproximal (IP) Cleaning Prototype
Description: Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sonicare Interproximal (IP) Cleaning Prototype
Description: Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.
Study: NCT00057811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasburicase
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV or orally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone sodium succinate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone sodium succinate
Description: Given IT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03356873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D supplementation

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04039880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorofim
Description: single oral dose (120 mg, 3.7 MBq)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorofim
Description: single oral dose (120 mg, 3.7 MBq)
Study: NCT03774199

Intervention type: DEVICE
Group type: OTHER
Intervention: NightOwl
Description: The NightOwl is a finger and/or forehead mounted device with, among other functions, the capability to acquire double-wavelength PPG, from which SpO2 can be derived
Study: NCT02109458

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation guided bronchoscopy
Description: Navigation guided transthoracic needle aspiration (N-TTNA) and navigation guided bronchoscopy (NB); guidance system is by Veran Medical Technologies, Inc.
Study: NCT01710280

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High-fat meal containing native palm olein

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-fat meal containing interesterified palm olein
Study: NCT04448730

Intervention type: DIAGNOSTIC_TEST
Intervention: serum marker levels
Description: two groups comparisons

Intervention type: DIAGNOSTIC_TEST
Intervention: serum marker levels
Description: two groups comparisons
Study: NCT03492567

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood test
Description: Blood draw (max 15 ml)
Study: NCT03277248

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ublituximab
Description: Administered as an IV infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriflunomide
Description: Film coated tablets administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Placebo
Description: Administered orally.
Study: NCT02136823

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic muscle stretching
Study: NCT02942589

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meal portion size
Study: NCT02130726

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally-invasive gastrectomy
Description: Patients allocated to the 'Minimally-invasive gastrectomy' arm will receive total gastrectomy via laparoscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Gastrectomy
Description: patients allocated to the 'Open gastrectomy' group will receive total gastrectomy via laparotomy
Study: NCT01455571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM781-36B
Description: Q1DX14/2W for 3W HM781-36B
Study: NCT01193790

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coblation channeling
Description: The combination of the energy and the fluid creates a plasma field containing highly ionized particles (coblation). The ionized particles have sufficient energy to break organic molecular bonds that can remove tissue selectively without excessive heat production and subsequent damage to the surrounding tissue. Treatment of the tonsillar crypts and tissue by coblation may decrease antigen and immune system interaction and inflammation.
Study: NCT02431585

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: gluten

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: placebo
Study: NCT04397068

Intervention type: PROCEDURE
Group type: OTHER
Intervention: phaco-vitrectomy
Description: phaco-vitrectomy. No other involvement drug or device. Standard of care procedure
Study: NCT04789746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: adapted Chicago Run running program
Description: The intervention being piloted is a 6-8 week running program modified from a running curriculum designed for school-aged children. The children will use a RaceRunner device to facilitate their participation, but this device is not explicitly evaluated in this study. Depending on transportation, they may be given access to the device in their home or school between sessions after it has been fit for them. If given access, guardians will be instructed on care and usage.
Study: NCT01877330

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block for shoulder arthroscopy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene block for shoulder arthroscopy
Study: NCT00468767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vernakalant Injection 20 mg/mL
Study: NCT02257814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preschool PATHS

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tools of the Mind
Study: NCT06313281

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Antiseptic preparation prior to transnasal skull base surgery
Description: The patient received one of three antiseptic preparation before transnasal skull base surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Antiseptic preparation prior to transnasal skull base surgery
Description: The patient received one of three antiseptic preparation before transnasal skull base surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Antiseptic preparation prior to transnasal skull base surgery
Description: The patient received one of three antiseptic preparation before transnasal skull base surgery
Study: NCT02491658

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UC-MSCs
Description: Psoriasis Vulgaris patients will receive 6 times UC-MSCs infusions (each time 1×10\^6/kg). The first time to fourth time will be given once a week for successive 4 weeks, then the last two times will be given once every two weeks.
Study: NCT02328573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communal singing
Study: NCT02650284

Intervention type: DEVICE
Group type: OTHER
Intervention: Stryker Triathlon Primary Total Knee System
Description: Total Knee Replacement